Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 7/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | CRHBP | P24387 | 1/20 | 0.47 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | TYR | P14679 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | TAS2R38 | P59533 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29028454 | 0.84 | KMT2A (0.57) | KMT2AMEN1SMN1; SMN2ALDH1A1NPSR1 | |
| SCHEMBL9082914 | 0.80 | ALDH1A1 (0.50) | KMT2AMEN1SMN1; SMN2ALDH1A1NPSR1 | |
| SCHEMBL28420044 | 0.78 | ALDH1A1 (0.48) | KMT2AMEN1SMN1; SMN2ALDH1A1NPSR1 | |
| SCHEMBL27839869 | 0.78 | ALDH1A1 (0.48) | KMT2AMEN1SMN1; SMN2ALDH1A1NPSR1 | |
| SCHEMBL11875734 | 0.78 | ALDH1A1 (0.48) | KMT2AMEN1SMN1; SMN2ALDH1A1NPSR1 | |
| SCHEMBL2152542 | 0.78 | KMT2A (0.66) | KMT2AMEN1SMN1; SMN2ALDH1A1NPSR1 | |
| SCHEMBL29028452 | 0.77 | KMT2A (0.59) | KMT2AMEN1SMN1; SMN2ALDH1A1NPSR1 | |
| SCHEMBL2640797 | 0.77 | KMT2A (0.48) | KMT2AMEN1SMN1; SMN2ALDH1A1NPSR1 | |
| SCHEMBL28602736 | 0.76 | KMT2A (0.47) | KMT2AMEN1SMN1; SMN2ALDH1A1NPSR1 | |
| SCHEMBL28151420 | 0.76 | KMT2A (0.47) | KMT2AMEN1SMN1; SMN2ALDH1A1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7897720-B2 | Method for removing catalyst residues from polymer solution and polymers purified by the method | LG CHEM, LTD. (KR) | 2011-03-01 | — | — | US | claimed |
| CN-1970537-B | Process for manufacturing diphenylthiocarbazone | SHANGHAI SSS REAGENT CO LTD | 2010-05-05 | — | — | CN | claimed |
| US-20100029900-A1 | METHOD FOR REMOVING CATALYST RESIDUES FROM POLYMER SOLUTION AND POLYMERS PURIFIED BY THE METHOD | LG CHEM, LTD. (KR) | 2010-02-04 | — | — | US | claimed |
| WO-2008056938-A1 | METHOD FOR REMOVING CATALYST RESIDUES FROM POLYMER SOLUTION AND POLYMERS PURIFIED BY THE METHOD | LG CHEM, LTD. (KR) | 2008-05-15 | — | — | WO | claimed |
| CN-1970537-A | Process for manufacturing diphenylthiocarbazone | SHANGHAI SSS REAGENT CO LTD (CN) | 2007-05-30 | — | — | CN | claimed |
| EP-3508474-B1 | NOVEL THERAPEUTIC AGENT FOR DIABETES | JAPAN CHEM RES (JP) | 2023-05-17 | — | — | EP | disclosed |
| CN-109336800-B | DHNB (dehydroepiandrosterone) condensed phenylthiosemicarbazide compound as well as preparation method and application thereof | 江西中医药大学 | 2022-11-29 | — | — | CN | disclosed |
| US-10759749-B2 | Therapeutic agent for diabetes | JCR PHARMACEUTICALS CO., LTD. (JP) | 2020-09-01 | — | — | US | disclosed |
| US-10759749-B2 | Therapeutic agent for diabetes | JCR PHARMACEUTICALS CO., LTD. (JP) | 2020-09-01 | — | — | US | disclosed |
| EP-3508474-A1 | NOVEL THERAPEUTIC AGENT FOR DIABETES | JCR Pharmaceuticals Co., Ltd. (JP) | 2019-07-10 | — | — | EP | disclosed |
| EP-3508474-A1 | NOVEL THERAPEUTIC AGENT FOR DIABETES | JCR Pharmaceuticals Co., Ltd. (JP) | 2019-07-10 | — | — | EP | disclosed |
| US-20190202781-A1 | NOVEL THERAPEUTIC AGENT FOR DIABETES | JCR PHARMACEUTICALS CO., LTD. (JP) | 2019-07-04 | — | — | US | disclosed |
| US-20190202781-A1 | NOVEL THERAPEUTIC AGENT FOR DIABETES | JCR PHARMACEUTICALS CO., LTD. (JP) | 2019-07-04 | — | — | US | disclosed |
| WO-2018043399-A1 | NOVEL THERAPEUTIC AGENT FOR DIABETES | ＪＣＲファーマ株式会社 | 2018-03-08 | — | — | WO | disclosed |
| EP-1686167-B1 | LUBRICATING OIL ADDITIVE AND LUBRICATING OIL COMPOSITION | NIPPON OIL CORP (JP) | 2016-05-25 | — | — | EP | disclosed |
| US-7897720-B2 | Method for removing catalyst residues from polymer solution and polymers purified by the method | LG CHEM, LTD. (KR) | 2011-03-01 | — | — | US | disclosed |
| CN-1970537-B | Process for manufacturing diphenylthiocarbazone | SHANGHAI SSS REAGENT CO LTD | 2010-05-05 | — | — | CN | disclosed |
| US-20100029900-A1 | METHOD FOR REMOVING CATALYST RESIDUES FROM POLYMER SOLUTION AND POLYMERS PURIFIED BY THE METHOD | LG CHEM, LTD. (KR) | 2010-02-04 | — | — | US | disclosed |
| WO-2008056938-A1 | METHOD FOR REMOVING CATALYST RESIDUES FROM POLYMER SOLUTION AND POLYMERS PURIFIED BY THE METHOD | LG CHEM, LTD. (KR) | 2008-05-15 | — | — | WO | disclosed |
| CN-1970537-A | Process for manufacturing diphenylthiocarbazone | SHANGHAI SSS REAGENT CO LTD (CN) | 2007-05-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190202781-A1 | NOVEL THERAPEUTIC AGENT FOR DIABETES | GPR119, IAPP, DPP4 | KMT2A 3897/4885MEN1 4253/4885SMN1; SMN2 3948/4885 |
| US-10759749-B2 | Therapeutic agent for diabetes | GPR119, IAPP, DPP4 | KMT2A 3159/4885MEN1 3662/4885SMN1; SMN2 3104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.